Merck & Co., Inc. Proceeds from Debt, Net of Issuance Costs
Merck & Co., Inc. (MRK) reported Proceeds from Debt, Net of Issuance Costs of $5.00 billion for the 1-month period ending 2019-03-31, per its 10-K filed 2020-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2020-02-26
- 2019-03-31: Proceeds from Debt, Net of Issuance Costs 1 month $5.00B.
- 2016-11-30: Proceeds from Debt, Net of Issuance Costs 1 month $1.10B.
- 2015-02-28: Proceeds from Debt, Net of Issuance Costs 1 month $7.90B.
- 2014-10-31: Proceeds from Debt, Net of Issuance Costs 1 month $3.10B.
| Period end | Proceeds from Debt, Net of Issuance Costs 1 month |
|---|---|
| 2019-03-31 | $5.00B 10-K · filed 2020-02-26 |
| 2016-11-30 | $1.10B 10-K · filed 2017-02-28 |
| 2015-02-28 | $7.90B 10-K · filed 2016-02-26 |
| 2014-10-31 | $3.10B 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |